Original language | English |
---|---|
Journal | The Lancet |
Volume | 398 |
Issue number | 10303 |
Pages (from-to) | 838-839 |
Number of pages | 2 |
ISSN | 0140-6736 |
DOIs | |
Publication status | Published - 04.09.2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Towards a European strategy to address the COVID-19 pandemic. / Priesemann, Viola; Balling, Rudi; Bauer, Simon et al.
In: The Lancet, Vol. 398, No. 10303, 04.09.2021, p. 838-839.Research output: Journal Articles › Letters › peer-review
TY - JOUR
T1 - Towards a European strategy to address the COVID-19 pandemic
AU - Priesemann, Viola
AU - Balling, Rudi
AU - Bauer, Simon
AU - Beutels, Philippe
AU - Valdez, André Calero
AU - Cuschieri, Sarah
AU - Czypionka, Thomas
AU - Dumpis, Uga
AU - Glaab, Enrico
AU - Grill, Eva
AU - Hotulainen, Pirta
AU - Iftekhar, Emil N.
AU - Krutzinna, Jenny
AU - Lionis, Christos
AU - Machado, Helena
AU - Martins, Carlos
AU - McKee, Martin
AU - Pavlakis, George N.
AU - Perc, Matjaž
AU - Petelos, Elena
AU - Pickersgill, Martyn
AU - Prainsack, Barbara
AU - Rocklöv, Joacim
AU - Schernhammer, Eva
AU - Szczurek, Ewa
AU - Tsiodras, Sotirios
AU - Van Gucht, Steven
AU - Willeit, Peter
N1 - Funding Information: RB is a shareholder of the Information Technology For Translational Medicine research institute. SB reports grants from Netzwerk Universitätsmedizin. PB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer, GlaxoSmithKlein, and European Commission IMI, unrelated to this Correspondence. CL reports grants from the University of Oxford, the National Centre for Smoking Cessation and Training, Gilead Sciences, and the European Commission's Horizon 2020, unrelated to this Correspondence, all under the agreement and control of the Special Committee for Research Grants of the University of Crete, Greece. GNP's contribution is in his personal capacity; the opinions expressed are the author's own and do not reflect the views of the National Institutes of Health (NIH), the Department of Health and Human Services, or the US Government. GNP's patents and company interactions are managed through the NIH. EP reports grants from the European Commission and personal fees from the European Commission, Maastricht University, Charité – Universitätsmedizin Berlin, and the Swedish Healthcare Academy, unrelated to this Correspondence. MPi reports grants and personal fees from Wellcome and the Economic and Social Research Council, grants from the Medical Research Council, and personal fees from the Research Foundation Flanders, unrelated to this Correspondence. BP is a member of the Austrian National Bioethics Committee and has been a member of the European Group on Ethics in Science and New Technologies (2017–21). Projects in the laboratory of ESz are co-funded by Merck Healthcare. All other authors declare no competing interests. Acknowledgements of funding sources are stated in the appendix . Additional information about the estimation of ICU admissions and translated versions of this Correspondence is available in the appendix.
PY - 2021/9/4
Y1 - 2021/9/4
UR - http://www.scopus.com/inward/record.url?scp=85114192869&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)01808-0
DO - 10.1016/S0140-6736(21)01808-0
M3 - Letters
C2 - 34384539
AN - SCOPUS:85114192869
VL - 398
SP - 838
EP - 839
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 10303
ER -